Filing Flows › Companies › Monte Rosa Therapeutics › Report card
Monte Rosa Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 5 reports beat the EPS estimate
Monte Rosa Therapeutics (GLUE) beat the analysts' EPS estimate in 2 of its last 5 reports (40%), by +4.2% on average.
Beat rate40% of 5
Average surprise+4.2%
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | −$0.20 | $0.03 | +114.9% | $54.4M |
| Q2 2026 | Aug 6, 2026 | −$0.37 | −$0.43 | -17.6% | $9.0M |
| Q1 2026 | May 7, 2026 | −$0.38 | −$0.45 | -19.1% | $4.2M |
| Q4 2025 | Mar 17, 2026 | −$0.34 | −$0.55 | -63.4% | $2.8M |
| Q3 2025 | Nov 6, 2025 | −$0.35 | −$0.33 | +6.4% | $12.8M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Monte Rosa Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.